Rhenman & Partners Asset Management Ab Arcellx, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $959 Million
- Q4 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Arcellx, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 43,500 shares of ACLX stock, worth $2.73 Million. This represents 0.35% of its overall portfolio holdings.
Number of Shares
43,500
Previous 32,000
35.94%
Holding current value
$2.73 Million
Previous $2.67 Million
23.95%
% of portfolio
0.35%
Previous 0.22%
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$274 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$235 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$220 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$218 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$209 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.75B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...